Xenios AG, a developer of lung and heart assist therapies, has combined its novalung, i-cor, and medos websites into www.xenios-ag.com to further advance the Xenios platform. With the new Xenios website, the Heilbronn-based medical device company further advances its lung and heart assist therapy platform. The corporate website now integrates the websites of the novalung, medos, and i-cor therapy brands.
A press release reports that as the leading provider of a lung and heart assist platform, the focus of the new online presence is on both therapy and product. Customers and business partners will find tailored information at Xenios Campus, an online platform for clinical support, therapy information, and training. The integrated Xenios Academy continues the tradition of the recognised novalung academy, and offers therapy-specific training options both on site at hospitals and in training centres.